Movers and SHAKERS
Onconova Therapeutics (ONTX)
New Data Shows Rigosertib Efficacy In Lung Cancer
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Data To Be Presented At Scientific Conference. Onconova is scheduled to present data from the Phase 1/2a clinical trial evaluating the combination of rigosertib and nivolumab (Opdivo) in non-small cell lung cancer (NSCLC) today at 11:30 at the 3rd Annual RAS Targeted Drug Development Summit. The company released efficacy data this morning, and plans to hold a conference call to discuss the data this afternoon.
Study Design. The Phase 1/2a trial tests rigosertib in combination with the checkpoint inhibitor nivolumab, a PD-1 inhibitor. Prior studies have shown that Rigosterib blocks multiple RAS mutations and also stimulates stronger immune responses. The trial was designed to combine the two drugs in patients with tumors that test positive for mutations in the KRAS signaling pathway (KRAS+) ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.